Ventyx Biosciences, Inc. (VTYX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ventyx Biosciences, Inc. (“Ventyx” or “the Company”) (NASDAQ: VTYX). Investors who purchased Ventyx securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Ventyx has violated federal securities laws.
Ventyx is the subject of an article published by STAT on November 6, 2023. According to the article, “Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial.” Based on this news, shares of Ventyx fell by more than 76% in after hours trading on the same day.
If you are aware of any facts relating to this investigation or purchased Ventyx securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.